Tyra Biosciences: Thoughts from our Vegas healthcare conference fireside and investor dinner

Research evidence excerpt

Tyra Biosciences: Thoughts from our Vegas healthcare conference fireside and investor dinner

Accessible version

Tyra Biosciences

Thoughts from our Vegas healthcare

conference fireside and investor dinner

Maintain Rating: BUY | PO: 37.00 USD | Price: 36.19 USD

Differentiated profile emerging with key readouts ahead 14 May 2026

We hosted Tyra for a fireside chat and investor dinner at our Healthcare Conference, Equity

with discussion focused on upcoming catalysts across its FGFR3 program in urologic

Jason Zemansky

oncology and rare disease. Supported by positive messaging and tone, we came away Research Analyst

more favorable on the outlook for dabogratinib (dabo) to clear relevant clinical hurdles in BofAS +1 646 855 4280

upcoming readouts in NMIBC, achondroplasia, and LG-UTUC—creating multiple paths to jason.zemansky@bofa.com

value creation, with each representing a potential blockbuster opportunity. While TYRA Jacqueline Plesset

shares have outperformed YTD (+38% vs. NBI +6%), largely, in our view, reflecting Research Analyst BofAS

strengthening sentiment around the story, we’d argue the fundamentals still undervalue +1 646 855 0014

this multi-indication opportunity, with the story well positioned for a meaningful jacqueline.plesset@bofa.com

inflection ahead. Maintain Buy, $37 PO.

‘302 could de-risk remaining programs, adding to upside Stock Data

Representing, according to Tyra, the majority of the combined potential opportunity, the

Price 36.19 USD

bladder cancer franchises were a central focus of the discussion, given potential to

Price Objective 37.00 USD

improve clinical outcomes and patient quality of life—supporting meaningful value

Date Established 12-Feb-2026

creation. In NMIBC, the August SURF302 readout should clarify whether dabo can deliver